A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
PHASE1CompletedINTERVENTIONAL
Enrollment
85
Participants
Timeline
Start Date
Not specified
Study Completion Date
November 30, 1995
Conditions
HIV Infections
Interventions
DRUG
Zidovudine
DRUG
Didanosine
Trial Locations (1)
900276016
Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00000652 - A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection | Biotech Hunter | Biotech Hunter